Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma

[1] Kamangar F(2006)Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 2137-2150

[2] Dores GM(2008)Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European organisation for research and treatment of cancer (EORTC)-gastrointestinal cancer group Eur J Cancer 44 182-194

[3] Anderson WF(2009)Gastric cancer Crit Rev Oncol Hematol 71 127-164

[4] Van Cutsem E(2006)Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data J Clin Oncol 24 2903-2909

[5] Van de Velde C(2006)Standard of care for gastric cancer based on meta-analysis? Treading on thin ice or it is very nice! J Clin Oncol 24 5473-5474

[6] Roth A(2009)Optimising treatment regimens for the management of advanced gastric cancer Ann Oncol 20 605-608

[7] Catalano V(2008)Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction Ann Oncol 19 1450-1457

[8] Labianca R(2006)Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group J Clin Oncol 24 4991-4997

[9] Beretta GD(2007)Docetaxel for advanced gastric cancer? J Clin Oncol 25 2490-2491

[10] Wagner AD(2007)Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol 25 3188-3190

[1] Kamangar F(2006)Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 2137-2150

[2] Dores GM(2008)Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European organisation for research and treatment of cancer (EORTC)-gastrointestinal cancer group Eur J Cancer 44 182-194

[3] Anderson WF(2009)Gastric cancer Crit Rev Oncol Hematol 71 127-164

[4] Van Cutsem E(2006)Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data J Clin Oncol 24 2903-2909

[5] Van de Velde C(2006)Standard of care for gastric cancer based on meta-analysis? Treading on thin ice or it is very nice! J Clin Oncol 24 5473-5474

[6] Roth A(2009)Optimising treatment regimens for the management of advanced gastric cancer Ann Oncol 20 605-608

[7] Catalano V(2008)Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction Ann Oncol 19 1450-1457

[8] Labianca R(2006)Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group J Clin Oncol 24 4991-4997

[9] Beretta GD(2007)Docetaxel for advanced gastric cancer? J Clin Oncol 25 2490-2491

[10] Wagner AD(2007)Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol 25 3188-3190